vs
Side-by-side financial comparison of Elanco Animal Health Inc (ELAN) and Jazz Pharmaceuticals plc (JAZZ). Click either name above to swap in a different company.
Jazz Pharmaceuticals plc is the larger business by last-quarter revenue ($1.2B vs $1.1B, roughly 1.0× Elanco Animal Health Inc). Jazz Pharmaceuticals plc runs the higher net margin — 17.0% vs -24.1%, a 41.1% gap on every dollar of revenue. On growth, Elanco Animal Health Inc posted the faster year-over-year revenue change (12.2% vs 10.1%). Jazz Pharmaceuticals plc produced more free cash flow last quarter ($345.8M vs $46.0M). Over the past eight quarters, Jazz Pharmaceuticals plc's revenue compounded faster (15.2% CAGR vs -2.6%).
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
ELAN vs JAZZ — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $1.2B |
| Net Profit | $-276.0M | $203.5M |
| Gross Margin | 51.5% | — |
| Operating Margin | -22.6% | 21.2% |
| Net Margin | -24.1% | 17.0% |
| Revenue YoY | 12.2% | 10.1% |
| Net Profit YoY | -3350.0% | 6.5% |
| EPS (diluted) | $-0.55 | $3.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.1B | $1.2B | ||
| Q3 25 | $1.1B | $1.1B | ||
| Q2 25 | $1.2B | $1.0B | ||
| Q1 25 | $1.2B | $897.8M | ||
| Q4 24 | $1.0B | $1.1B | ||
| Q3 24 | $1.0B | $1.1B | ||
| Q2 24 | $1.2B | $1.0B | ||
| Q1 24 | $1.2B | $902.0M |
| Q4 25 | $-276.0M | $203.5M | ||
| Q3 25 | $-34.0M | $251.4M | ||
| Q2 25 | $11.0M | $-718.5M | ||
| Q1 25 | $67.0M | $-92.5M | ||
| Q4 24 | $-8.0M | $191.1M | ||
| Q3 24 | $364.0M | $215.1M | ||
| Q2 24 | $-50.0M | $168.6M | ||
| Q1 24 | $32.0M | $-14.6M |
| Q4 25 | 51.5% | — | ||
| Q3 25 | 53.4% | — | ||
| Q2 25 | 57.5% | — | ||
| Q1 25 | 57.3% | — | ||
| Q4 24 | 50.9% | — | ||
| Q3 24 | 52.2% | — | ||
| Q2 24 | 58.2% | — | ||
| Q1 24 | 57.3% | — |
| Q4 25 | -22.6% | 21.2% | ||
| Q3 25 | -4.4% | 5.1% | ||
| Q2 25 | 2.0% | -65.6% | ||
| Q1 25 | 5.0% | -6.2% | ||
| Q4 24 | -5.0% | 17.5% | ||
| Q3 24 | 54.3% | 24.7% | ||
| Q2 24 | -2.7% | 19.5% | ||
| Q1 24 | 1.0% | 7.3% |
| Q4 25 | -24.1% | 17.0% | ||
| Q3 25 | -3.0% | 22.3% | ||
| Q2 25 | 0.9% | -68.7% | ||
| Q1 25 | 5.6% | -10.3% | ||
| Q4 24 | -0.8% | 17.6% | ||
| Q3 24 | 35.3% | 20.4% | ||
| Q2 24 | -4.2% | 16.5% | ||
| Q1 24 | 2.7% | -1.6% |
| Q4 25 | $-0.55 | $3.34 | ||
| Q3 25 | $-0.07 | $4.08 | ||
| Q2 25 | $0.02 | $-11.74 | ||
| Q1 25 | $0.13 | $-1.52 | ||
| Q4 24 | $-0.01 | $2.97 | ||
| Q3 24 | $0.73 | $3.42 | ||
| Q2 24 | $-0.10 | $2.49 | ||
| Q1 24 | $0.06 | $-0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $545.0M | $1.4B |
| Total DebtLower is stronger | $3.9B | $5.4B |
| Stockholders' EquityBook value | $6.5B | $4.3B |
| Total Assets | $13.4B | $11.7B |
| Debt / EquityLower = less leverage | 0.60× | 1.24× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $545.0M | $1.4B | ||
| Q3 25 | $505.0M | $1.3B | ||
| Q2 25 | $539.0M | $1.2B | ||
| Q1 25 | $487.0M | $1.9B | ||
| Q4 24 | $468.0M | $2.4B | ||
| Q3 24 | $490.0M | $2.2B | ||
| Q2 24 | $416.0M | $1.4B | ||
| Q1 24 | $345.0M | $1.4B |
| Q4 25 | $3.9B | $5.4B | ||
| Q3 25 | $4.0B | $5.4B | ||
| Q2 25 | $4.1B | $5.4B | ||
| Q1 25 | $4.4B | $5.4B | ||
| Q4 24 | $4.3B | $6.1B | ||
| Q3 24 | $4.4B | $6.1B | ||
| Q2 24 | $5.7B | $5.7B | ||
| Q1 24 | $5.8B | $5.7B |
| Q4 25 | $6.5B | $4.3B | ||
| Q3 25 | $6.7B | $4.0B | ||
| Q2 25 | $6.8B | $3.7B | ||
| Q1 25 | $6.4B | $4.2B | ||
| Q4 24 | $6.1B | $4.1B | ||
| Q3 24 | $6.5B | $4.2B | ||
| Q2 24 | $5.9B | $3.8B | ||
| Q1 24 | $6.1B | $3.7B |
| Q4 25 | $13.4B | $11.7B | ||
| Q3 25 | $13.6B | $11.4B | ||
| Q2 25 | $13.7B | $10.9B | ||
| Q1 25 | $12.9B | $11.5B | ||
| Q4 24 | $12.6B | $12.0B | ||
| Q3 24 | $13.3B | $12.3B | ||
| Q2 24 | $13.8B | $11.4B | ||
| Q1 24 | $14.0B | $11.3B |
| Q4 25 | 0.60× | 1.24× | ||
| Q3 25 | 0.59× | 1.35× | ||
| Q2 25 | 0.61× | 1.45× | ||
| Q1 25 | 0.69× | 1.29× | ||
| Q4 24 | 0.70× | 1.49× | ||
| Q3 24 | 0.67× | 1.47× | ||
| Q2 24 | 0.96× | 1.52× | ||
| Q1 24 | 0.95× | 1.54× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $108.0M | $362.5M |
| Free Cash FlowOCF − Capex | $46.0M | $345.8M |
| FCF MarginFCF / Revenue | 4.0% | 28.9% |
| Capex IntensityCapex / Revenue | 5.4% | 1.4% |
| Cash ConversionOCF / Net Profit | — | 1.78× |
| TTM Free Cash FlowTrailing 4 quarters | $284.0M | $1.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.0M | $362.5M | ||
| Q3 25 | $219.0M | $474.6M | ||
| Q2 25 | $237.0M | $88.9M | ||
| Q1 25 | $-4.0M | $429.8M | ||
| Q4 24 | $177.0M | $398.6M | ||
| Q3 24 | $162.0M | $398.7M | ||
| Q2 24 | $200.0M | $331.4M | ||
| Q1 24 | $2.0M | $267.2M |
| Q4 25 | $46.0M | $345.8M | ||
| Q3 25 | $127.0M | $459.4M | ||
| Q2 25 | $180.0M | $75.9M | ||
| Q1 25 | $-69.0M | $415.9M | ||
| Q4 24 | $130.0M | $385.3M | ||
| Q3 24 | $120.0M | $388.0M | ||
| Q2 24 | $166.0M | $324.3M | ||
| Q1 24 | $-22.0M | $260.3M |
| Q4 25 | 4.0% | 28.9% | ||
| Q3 25 | 11.2% | 40.8% | ||
| Q2 25 | 14.5% | 7.3% | ||
| Q1 25 | -5.8% | 46.3% | ||
| Q4 24 | 12.7% | 35.4% | ||
| Q3 24 | 11.7% | 36.8% | ||
| Q2 24 | 14.0% | 31.7% | ||
| Q1 24 | -1.8% | 28.9% |
| Q4 25 | 5.4% | 1.4% | ||
| Q3 25 | 8.1% | 1.3% | ||
| Q2 25 | 4.6% | 1.2% | ||
| Q1 25 | 5.4% | 1.5% | ||
| Q4 24 | 4.6% | 1.2% | ||
| Q3 24 | 4.1% | 1.0% | ||
| Q2 24 | 2.9% | 0.7% | ||
| Q1 24 | 2.0% | 0.8% |
| Q4 25 | — | 1.78× | ||
| Q3 25 | — | 1.89× | ||
| Q2 25 | 21.55× | — | ||
| Q1 25 | -0.06× | — | ||
| Q4 24 | — | 2.09× | ||
| Q3 24 | 0.45× | 1.85× | ||
| Q2 24 | — | 1.97× | ||
| Q1 24 | 0.06× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ELAN
| Pet Health | $489.0M | 43% |
| Cattle | $296.0M | 26% |
| Poultry | $237.0M | 21% |
| Swine | $107.0M | 9% |
| Contract Manufacturing | $15.0M | 1% |
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
